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Adaptation to decreased oxygen tension is a fundamental
requirement of all living organisms. Two well understood adap-
tations in higher organisms to a decrease in oxygen delivery to the
tissues are an increase in respiratory rate and an increase in red
blood cell mass. These physiological adaptations are achieved by
specific oxygen sensing cells in the carotid body and kidney,
respectively. At a molecular level this adaptation to hypoxia
involves the specific regulation of hypoxia responsive genes such
as tyrosine hydroxylase and erythropoietin (Epo). New blood
vessel formation or angiogenesis is also an adaptive response to
cell and tissue hypoxia [1]. Indeed, the increased coronary collat-
eral circulation of the heart seen in coronary artery disease, tumor
angiogenesis that is required for tumor growth and metastasis,
and diabetic retinopathy are recognized as responses to hypoxia
[2—4]. Vascular endothelial growth factor (VEGF), also known as
vascular permeability factor, is a potent angiogenic factor and
endothelial cell-specific mitogen [5, 6] that is regulated by hypoxia
in vitro and in vivo [1]. Furthermore, the neovascular response
associated with many tumors as well as experimentally induced
retinopathy can be inhibited with neutralizing antiserum to VEGF
[4, 7]. VEGF thus appears to be an important mediator of hypoxia
induced angiogenesis in vivo. This review will describe studies that
we and others have performed investigating the mechanism of
hypoxic induction of VEGF.
Regulation of VEGF by hypoxia occurs at the level of the
steady state mRNA
VEGF mRNA has been demonstrated to be induced by hypoxia
8 to 30-fold in multiple cell lines in vitro [1, 8—10]. We have shown
that primary neonatal rat cardiac myocytes increase the level of
VEGF mRNA 25.0 11.4-fold by 24 hours of exposure to 1%
oxygen [9]. A significant increase in VEGF mRNA can be seen as
early as three hours after exposure to hypoxia. This increase in
mRNA is associated with a commensurate increase in VEGF
protein production and release into the tissue culture media [9],
arguing against a significant role for translational regulation of
VEGF synthesis with hypoxia.
Specific riboprobes that allow for the identification of the 121,
165, 189 and 206 amino acid isoforms of VEGF were developed
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and revealed marked differences in the steady state levels of the
mRNA for these isoforms in different cell lines and tissues.
However, we have not observed a significant change in the relative
amounts of the different isoforms in response to hypoxia [9].
Transition metals stimulate VEGF production
It has been hypothesized that the ability of the transition metals
cobalt and manganese to stimulate Epo production is due to their
effect on an oxygen-sensing heme protein whose activity changes
depending on the presence or absence of oxygen binding to the
heme moiety [Ii]. Cobalt and manganese can substitute for iron
in the protoporphyrin ring, but the resulting metal protoporphy-
rins bind oxygen either poorly or not at all, thus locking the
protein in a deoxy conformation and simulating the deoxy state.
We have demonstrated that cobalt and manganese can stimulate
VEGF mRNA in multiple cell lines [8, 91. The stimulation of
VEGF by transition metals provides evidence for a common
oxygen-sensing system regulating the expression of VEGF and
Epo.
Regulation of hypoxic induction of VEGF mRNA by activated
second messenger systems
Hypoxia has been shown to increase calcium influx and mem-
brane bound protein kinase C in a variety of cell types. Further-
more, these same second messengers have been shown to stimu-
late VEGF mRNA [12]. However, only protein kinase C
inhibition with H7 (20 kM), as opposed to protein kinase A or
calcium calmodulin kinase II inhibition, demonstrated any signif-
icant inhibition of VEGF mRNA induction with hypoxia [9]. This
suggests that induction of VEGF synthesis may occur through
more than one pathway.
Transcriptional rate for VEGF is increased threefold by
hypoxia
While the steady state mRNA for VEGF is increased 8- to
30-fold by hypoxia, we and others have found that transcriptional
rate for VEGF as assessed by nuclear run off transcription assay
is only increased two- to threefold by hypoxia [10, 131. In order to
investigate the cis-regulatory sequences that mediate this re-
sponse to hypoxia, we cloned the rat genomic sequences encoding
VEGF. A 2 kb fragment containing VEGF flanking sequence was
used in transient transfection assays with the luciferase reporter
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gene. A fourfold increase in reporter gene activity was observed
when cells were exposed to 1% oxygen [101. Inclusion of VEGF 5'
untranslated or 3' untranslated sequences in their native orienta-
tions relative to the reporter gene did not result in any significant
further increase in the hypoxic induction mediated by the 2 kb
promoter fragment in transient transfection assays.
Identification of a functional HIF-1 site in the VEGF 5'
promoter
Multiple constructs containing VEGF 5' promoter fragments
were generated by deletional analysis of the construct described
above. Initially a 215 bp fragment was identified that was capable
of conferring hypoxia inducibility to the reporter gene. This
fragment was functional in this capacity in either orientation
relative to a heterologous promoter. Within this fragment a region
of 28 bp that were 100% conserved between the rat and human
VEGF genes was identified and oligonucleotides corresponding
to this sequence were generated [10]. This synthetic site was
placed 5' to the minimal VEGF promoter in transient expression
assays and conferred a significant increase in the hypoxia/nor-
moxia ratio of reporter gene activity. Introduction of a three base
pair change, specifically in a potential hypoxia-inducible factor 1(HIF-1) [14] binding site in the 28 bp sequence, resulted in
abrogation of this hypoxia inducible response [10].
In electromobility band shift assays, a specific hypoxia inducible
DNA band shift was observed with this 28 bp radiolabeled VEGF
DNA sequence. This band shift was competitively blocked by an
excess of either the unlabeled 28 bp VEGF DNA sequence or by
an oligonucleotide containing the HIF-1 binding site from the
Epo hypoxia responsive enhancer. Conversely, the mutant oligo-
nucleotide was unable to competitively inhibit the hypoxia induc-
ible band shift with the wild-type sequence, nor was it able to
specifically retard a hypoxia-inducible species in the band shift
assay.
Other cis-elements and trans-acting factors are likely to be
involved in the hypoxic induction of VEGF in addition to HIF-1.
For example the VEGF minimal promoter, which contains 3 SPI
sites, is modestly hypoxia-inducible in the transient transfection
reporter assay. SP1 binding is dependent on redox state with a
reducing environment (which occurs with hypoxia) stimulating
SP1 binding as detected by DNA band shift and reporter gene
assays [15]. Similarly, AP-1 which has several consensus cognate
binding sites in the VEGF promoter has been identified as a
redox-sensitive transcription factor [16]. It is interesting to note
that cooperativity between HIF-1 and other transcription factors
in the hypoxia inducible increase in the transcription rate has been
noted for other hypoxia inducible genes such as lactate dehydro-
genase [171 and Epo [18—20].
VEGF mRNA is stabilized by hypoxia
Preliminary studies using cycloheximide [1] as well as the
discrepancy between the degree of increase in steady-state VEGF
mRNA levels and the results of the nuclear run off studies
suggested that post-transcriptional mechanisms were active in the
hypoxic induction of VEGF. Actinomycin D chase experiments
performed by our lab and others [13, 21—23] have shown a 2.5- to
eightfold increase in the half life of VEGF mRNA with hypoxia.
Identification of sequences in the VEGF 3'UTR that mediate
the rapid turnover of VEGF mRNA and its stabilization by
hypoxia
The 3' region of the VEGF gene was cloned from both a
genomic and eDNA library [101. The transcription termination
site was mapped initially by Northern analysis using a battery of
genomic probes and definitively identified by the sequencing of
multiple independent eDNA inserts. The most frequently used
polyadenylation site was identified 1.9 kb 3' to the translation
termination codon. This 1.9 kb of sequence contains multiple
pentameric AUUUA sequence motifs that have previously iden-
tified to mediate the rapid turnover of numerous cytokine and
oncogene mRNAs [24].
An in vitro RNA degradation assay was developed using 32P
labeled, capped, polyadenylated VEGF 3' untranslated region
(UTR) transcripts synthesized in vitro with SP6 RNA polymerase
[23]. These transcripts were incubated with S-100 cytoplasmic
extract prepared from hypoxic or normoxic cells. The incubation
was terminated at defined time intervals and analyzed on a
formaldehyde agarose gel. After transfer to nylon membrane the
amount of primary undegraded transcript was quantified by
phosphorimaging analysis. Several VEGF 3' UTR transcripts
containing progressive deletions from the 3' end were assayed in
this system. Using only normoxic extracts, two regions of the 3'
UTR were identified that each independently resulted in a
twofold increase in VEGF stability when deleted in the in vitro
assay. These instability sequences co-localized with consensus
nonameric instability elements that have been identified as the
minimal elements capable of conferring rapid degradation to a
heterologous gene, and have been previously identified in multi-
ple cytokine and oncogene 3' UTRs [25, 26].
When comparing the stability of the full length VEGF 3' UTR
transcript in the RNA degradation assay using normoxic versus
hypoxic extracts, we observed a significant increase in stability of
the full length transcript with the hypoxic extracts. This preferen-
tial stability of the full-length transcript was lost upon progressive
deletional analysis of the VEGF 3' UTR commencing from the 3'
end, thus allowing localization of a region in the VEGF 3' UTR
that is critical for the hypoxic stabilization of VEGF 3' UTR
transcripts in this in vitro assay.
Identification of a hypoxia-inducible protein complex which
binds to the VEGF mRNA 3' untranslated region
RNA transcripts of different regions of the VEGF 3'-UTR
incubated with S100 extract permitted the identification by dcc-
tromobility band shift assay (EMSA) of both constitutive and
hypoxia-induced VEGF mRNA binding proteins [23]. The con-
stitutive protein complex was found to map between nucleotides
909-1255 (GenBank Accession #U22372) of the VEGF 3' UTR.
A region of this fragment was identified with high homology to a
RNA fragment previously identified in the tyrosine hydroxylase 3'
UTR that forms a hypoxia-inducible RNA-protein complex [27].
Furthermore, a 162 bp fragment of the tyrosine hydroxylase 3'
UTR, when present in 100-fold excess could completely inhibit
the formation of this constitutive VEGF RNA-protein complex.
A hypoxia-inducible RNA-protein complex was mapped by
EMSA between VEGF 3' UTR nucleotides 1412-1754 (GenBank
Accession No. U22372). This complex thus maps to a site within
a region of the VEGF mRNA 3' UTR identified in the in vitro
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Fig. 1. A simple schematic summary diagram of the regulation of Steady-state VEGF mRNA by hypoxia. (HIF-1) Hypoxia-inducible factor 1 mediates the
transcriptional activation of VEGF by hypoxia. The transcription start site was defined by primer extension and RNase protection assay. (Coding)
designates the open reading frame for the VEGF protein. The nonamer instability element, UUAUUUAUU, is a sequence motif that mediates the
rapid turnover of multiple cytokine mRNA including VEGF mRNA. The Hypoxia-Inducible Stability Region is a 500 base fragment of RNA critical
for the hypoxic stabilization of VEGF 3' UTR transcripts in an in vitro degradation assay and which forms a hypoxia-inducible RNA-protein complex.
The polyadenylation signal AITAAA that is predominately used to generate the 3.7 kb VEGF mRNA is indicated. Three additional potential
polyadenylation sites 5' to this site are not shown.
RNA degradation assay to be critical for its preferential stabili-
zation by S-100 extracts from hypoxic cells. This RNA-protein
complex was induced approximately twofold by EMSA using
hypoxic versus normoxic S-100 extracts. This complex was not
effectively competed with a 500-fold excess of iron response
element transcript or Epo 3' UTR transcripts. Proteinase K
treatment of the extracts completely inhibited formation of the
complex [23].
Negative regulation of hypoxia-inducible genes by the von
Hippel-Lindau protein
Solid tumor growth is dependent upon tumor angiogenesis
induced by angiogenic factors such as VEGF. This provides the
tumor with nutrients and oxygen as well as an ability to establish
metastasis via the circulatory system. Many tumor cell lines have
been demonstrated to constitutively overexpress VEGF via con-
stitutive stabilization of VEGF mRNA [22]. We have recently
demonstrated that one mechanism for this constitutive stabiliza-
tion of VEGF is via inactivation of the von Hippel-Lindau (VHL)
tumor suppresser gene [281. Inactivation of vHL protein has been
implicated in the pathogenesis of renal carcinomas and central
nervous system hemangioblastomas. These are highly vascular
tumors that overproduce angiogenic peptides such as VEGF.
Renal carcinoma cells lacking wild-type VHL were found to
produce elevated levels of mRNAs encoding VEGF, the glucose
transporter Glut-I, and platelet-derived growth factor B chain
under both normoxic and hypoxic conditions. Reintroduction of
the wild-type, hut not mutant, VHL into these cells specifically
inhibited the production of these mRNAs under normoxic condi-
tions, thus restoring the hypoxia inducibility of these genes.
Furthermore, the stability of VEGF mRNA was prolonged ap-
proximately fourfold in cells lacking wild-type VHL compared to
cells in which wild-type VHL had been reintroduced. Transient
transfection using the VEGF 5' promoter driving expression of a
luciferase reporter gene and nuclear run off studies failed to
demonstrate any difference in the hypoxic regulation of VEGF in
the mutant and wild type VHL cells. Thus, VHL appears to play
a critical role in the transduction of signals generated by changes
in ambient oxygen tension. Current studies are exploring potential
interactions between the VHL protein and the hypoxia-inducible
protein complex that binds to the VEGF mRNA 3' UTR dis-
cussed above.
Summary
The regulation of VEGF production is mediated by both
transcriptional and post-transcriptional mechanisms. A schematic
model of elements involved in hypoxic regulation of VEGF is
shown in Figure 1.
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